{"id":807,"date":"2021-02-01T05:10:47","date_gmt":"2021-02-01T05:10:47","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=807"},"modified":"2021-02-01T05:10:47","modified_gmt":"2021-02-01T05:10:47","slug":"30-jan-2021-tocilizumab-study-supports-the-use-of-tocilizumab-in-covid-19-ards-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/30-jan-2021-tocilizumab-study-supports-the-use-of-tocilizumab-in-covid-19-ards-patients\/","title":{"rendered":"(30 Jan 2021) Tocilizumab- study supports the use of tocilizumab in COVID-19 ARDS patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale<\/p>\n<p>https:\/\/doi.org\/10.7759\/cureus.12290<\/p>\n<p class=\"\">An observational study was conducted from Feb 2020 to May 2020 on COVID-19 ARDS patients with hyperinflammation.&nbsp; A total of 244 patients with COVID-19 were admitted, out of which 107 had ARDS. Thirty patients had both ARDS and hyperinflammation and received tocilizumab. The mean age was 62.5 years (SD: 13.5) and the majority were male (83%). The mean CRP pre-treatment was 217.5 mg\/L and post 48 to 72 hours of tocilizumab treatment was 98.5 mg\/L. Twenty-one patients (70%) also received concomitant intravenous (IV) methylprednisolone. Of the 30 patients, seven died and 20 recovered. Ten patients required intensive care unit admission and nine developed nosocomial infections. COVID-19-associated aspergillosis was diagnosed in three patients post tocilizumab treatment. Mortality was significantly higher in patients who developed a nosocomial infection and who required intermittent positive pressure ventilation (IPPV). Post-treatment, clinical improvement was observed in patients who had a median score of 5 on the WHO ordinal scale.&nbsp; Our study supports the use of tocilizumab in COVID-19 ARDS patients with a pre-treatment median WHO ordinal severity score of 5 and recommends the monitoring of nosocomial infections and opportunistic infections.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale https:\/\/doi.org\/10.7759\/cureus.12290 An observational study was conducted from Feb 2020 to May 2020 on COVID-19 ARDS patients with hyperinflammation.&nbsp; A total of 244 patients with COVID-19 were&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/30-jan-2021-tocilizumab-study-supports-the-use-of-tocilizumab-in-covid-19-ards-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(30 Jan 2021) Tocilizumab- study supports the use of tocilizumab in COVID-19 ARDS patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/807"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=807"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/807\/revisions"}],"predecessor-version":[{"id":808,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/807\/revisions\/808"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}